Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Immunogenetic Profiling of Dupilumab in Atopic Dermatitis
NCT03293030Phase 4Completed
- Sponsor
- University of California, San Francisco
- Start
- Oct 2018
- Primary completion
- Feb 2023
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of dupilumab in atopic dermatitis (AD), sponsored by University of California, San Francisco. Primary endpoint: Percent Change in CD4+ T Effector Cells Expressing IL4 at 12 weeks. Started Oct 2018; status: completed.
02
Drugs
03
Conditions
atopic dermatitis (AD)
Beyond the preview
Go deeper on NCT03293030.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03293030.